Sanofi appoints Ameet Nathwani as Chief Digital Officer

As Chief Digital Officer, Dr Ameet Nathwani will be responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.

New Delhi: Headquartered in Paris, drugmaker Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer.

As Chief Digital Officer, Dr Nathwani will be responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes. His mandate will include scaling up Sanofi’s ongoing portfolio of digital initiatives by developing broad external partnerships, building out internal infrastructures, and exploring new business opportunities for Sanofi in the digital space.

Read Also: Sanofi, Regeneron slashes price of cholesterol drug by 60 percent

“Over the last two years, we have made fast progress in creating an innovative portfolio of digital initiatives and novel partnerships,” said Olivier Brandicourt, Chief Executive Officer at Sanofi.

“With Ameet’s wide experience in digital health and analytics, we will be able to further advance our capabilities to re-invent not only the way we discover and develop medicines but the types of future products we may offer to patients around the world.”

Dr Nathwani joined Sanofi in May 2016 as Chief Medical Officer.

A U.K. citizen, born in Uganda and educated in the U.K., Dr Nathwani has more than 20 years of experience in the pharmaceutical industry. Prior to joining Sanofi, Dr Nathwani was the Global Head of Medical Affairs, Novartis Pharma AG and served as an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.

Read Also: Sanofi gets FDA nod to blood disorder drug Cablivi

He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. Dr Nathwani began his pharmaceutical career in 1994 when he joined Glaxo Group Research.

From 1994 to 2004, he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, Smith Kline Beecham and Glaxo Smith Kline, both in Europe and the U.S.

Read Also: Biomunex signs licensing agreement with Sanofi for development of antibodies

Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an Executive Master’s Degree in Business Administration.